Skip to the guide

Peptides for healing: what the evidence shows

Which peptides are used for tissue recovery, what has really been studied, what is still unknown, and when another option fits better. No promises, only sources.

Products in this guide

The short answer for each goal.

If your problem isThe approachWhat is in itPrice
A tendon, ligament or muscle injuryRecovery peptides, reviewed by a clinician firstBPC-157, alone or with TB-500Prescribed after a clinician review
Recovery after an injury, in more than one tissueA blend of several peptidesBPC-157, TB-500, GHK-Cu, KPV and similar blendsPrescribed after a clinician review
Skin that needs repair and collagen supportA copper peptide given by injectionGHK-CuPrescribed after a clinician review
An injury that needs a scan or surgeryAn exam first, not a peptideNo peptide replaces the examYour clinician decides

Each product has its own page with its composition and concentration. Products without a public price are prescribed after a clinician review.

How tissue repair works, and where the evidence stops.

Repair of a tissue usually happens in phases that overlap. The peptides in this guide have been studied in those phases mostly in animals and in cell cultures. None has a large trial in people that confirms it speeds healing.

  1. Inflammation

    The first response to an injury. Animal studies look at whether these peptides change that response [2].

  2. Cell migration

    Cells move to the injured area. This has been studied mostly in cell cultures and animal models.

  3. Blood supply

    New small vessels form to feed the tissue. Most of the data come from animals; human data are scarce.

  4. Collagen and matrix

    The tissue is rebuilt. A recent study in rats measured healing of the Achilles tendon [1].

The four phases are a simplification to help you read this guide. They are not a protocol.

The products, one by one.

Each card shows the composition and concentration as the pharmacy loads them. Your clinician sets the dose for your case. We do not publish dose figures here, because for most of these peptides there is no established human dose.

Single peptides

  • ARA-290

    Composition and concentration
    2 mg/mL, 5 mL vial
    How it is given
    Injection under the skin

    Prescribed after a clinician review

    Start intake
  • KPV

    Composition and concentration
    2 mg/mL, 5 mL vial
    How it is given
    Injection under the skin

    Prescribed after a clinician review

    Start intake
  • TB-500

    Composition and concentration
    3 mg/mL, 5 mL vial
    How it is given
    Injection under the skin

    Prescribed after a clinician review

    Start intake
  • BPC-157

    Composition and concentration
    1 mg/mL, 5 mL vial
    How it is given
    Injection under the skin

    From $209/mo

    View product
  • GHK-Cu

    Composition and concentration
    10 mg/mL, 5 mL vial
    How it is given
    Injection under the skin

    From $209/mo

    View product

Blends

  • GHK-Cu / BPC-157 / TB-500 / Epitalon

    Composition and concentration
    10 mg / 2 mg / 2 mg / 2 mg/mL, 5 mL vial5 mg / 2 mg / 2 mg / 2 mg/mL, 5 mL vial
    How it is given
    Injection under the skin

    Prescribed after a clinician review

    Start intake
  • GHK-Cu / BPC-157 / TB-500

    Composition and concentration
    10 mg / 2 mg / 2 mg/mL, 5 mL vial
    How it is given
    Injection under the skin

    From $229/mo

    View product
  • GHK-Cu / BPC-157 / TB-500 / KPV

    Composition and concentration
    10 mg / 2 mg / 2 mg / 2 mg/mL, 5 mL vial
    How it is given
    Injection under the skin

    From $229/mo

    View product
  • BPC-157 / TB-500

    Composition and concentration
    1 mg / 1 mg/mL, 5 mL vial
    How it is given
    Injection under the skin

    From $229/mo

    View product
  • Tesamorelin / CJC-1295 / Ipamorelin / BPC-157

    Composition and concentration
    2 mg / 1.2 mg / 2.4 mg / 2 mg/mL, 5 mL vial
    How it is given
    Injection under the skin

    Prescribed after a clinician review

    Start intake
  • Tesamorelin / CJC-1295 / Ipamorelin 2.5 / BPC-157

    Composition and concentration
    2 mg / 1.2 mg / 2.5 mg / 2 mg/mL, 5 mL vial
    How it is given
    Injection under the skin

    Prescribed after a clinician review

    Start intake
  • Thymosin Alpha-1 / BPC-157 / KPV / LL-37

    Composition and concentration
    1 mg / 1 mg / 0.4 mg / 0.2 mg/mL, 5 mL vial
    How it is given
    Injection under the skin

    Prescribed after a clinician review

    Start intake
  • GHK-Cu / CJC-1295 / Ipamorelin / TB-500

    Composition and concentration
    10 mg / 1.2 mg / 2.4 mg / 0.4 mg/mL, 5 mL vial
    How it is given
    Injection under the skin

    Prescribed after a clinician review

    Start intake
  • Semax / Selank / BPC-157 / KPV

    Composition and concentration
    1 mg / 1 mg / 2 mg / 2 mg/mL, 5 mL vial1 mg / 1 mg / 5 mg / 5 mg/mL, 5 mL vial
    How it is given
    Injection under the skin

    Prescribed after a clinician review

    Start intake

What the evidence shows and what it does not.

Most of what has been published comes from animals, cell cultures and reviews. The few human data are small pilot studies or are not controlled.

What exists

  • An animal study of Achilles tendon healing in rats, comparing BPC-157 and TB-500 [1].
  • Reviews that summarize the BPC-157 data for tissue repair and pain [2][3].
  • Studies of GHK-Cu applied to the skin, where it is most often used [4].
  • Eye trials of thymosin beta-4, the protein TB-500 is named after [5]. TB-500 is a synthetic fragment, not that same protein.

What is missing

  • Large trials in people that confirm these products repair tendons or muscle.
  • Human trials of most of the blends, which have only been tested in animals or not at all.
  • An established human dose for several of these peptides. The dose on each product page is set by your clinician.
  • Sources from suppliers and online communities are not studies, and we do not use them as evidence.

Numbers in brackets point to the reference list at the end of the guide.

Who should not use them, and when another option fits better.

These are the cases where a clinician should not start a peptide, or should wait. The list is not complete: your clinician reviews your history before any prescription.

SituationWhy
Pregnancy, breastfeeding or trying to conceiveThere are not enough data in pregnant people. Your clinician reviews this first.
Active cancer or a recent history of cancerThese peptides have not been studied in people with active cancer. Your clinician decides before anything else.
An injury that needs surgery or imagingA tear or a serious injury is examined first. A peptide does not replace the exam.
Kidney or liver disease, or poorly controlled diabetesThese organs process and clear many substances. Your clinician checks your case.
You only need pain relief or an immediate fixSome injuries are better treated another way. Your clinician says which.

What to expect, and when.

There are no validated timelines in people for these peptides. What you can do is agree with your clinician what to watch and how often to review it.

  • What to measure: the function you care about, such as pain or range of movement in the activity that matters to you, noted at the start.
  • When to review: at the follow-up visits your clinician schedules.
  • What not to expect: a peptide that replaces rehabilitation or the examination of an injury.

Tests and monitoring your clinician decides.

Your clinician decides which tests to order before you start and during treatment, based on your history. They tell you which ones and when.

  • Before: your full history and the examination your clinician considers necessary.
  • During: review at the visits, with the tests your clinician orders.

References

Only studies and reviews indexed in PubMed, with the title and year as they appear there.

  1. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg, 2026
  2. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. Int J Mol Sci, 2026
  3. Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review. Pharmaceuticals (Basel), 2026
  4. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. Bioimpacts, 2025
  5. Thymosin beta 4 and the eye: the journey from bench to bedside. Expert Opin Biol Ther, 2018

Common questions

Which peptide is best for healing?

It depends on the injury and on your history. None of these peptides has large trials in people. Your clinician chooses according to your case.

How long do they take to work?

There are no validated timelines in people. Agree with your clinician what to watch and when to review it.

Do they actually work?

Most of the data come from animals and reviews. The human data are few, mostly small or not controlled.

Are they legal?

They are compounded medications. They are not FDA-approved for safety, efficacy or quality. A pharmacy licensed in the United States prepares them with a prescription.

How much do they cost?

Products with a public price show it on their page. The others are prescribed after a clinician review, so start with the intake to learn about your case.

Can BPC-157 and TB-500 be used together?

We sell a blend of the two, but there are no human trials of that combination. Your clinician decides whether it makes sense for you.

Start with your case and a clinician.

Complete the intake. A physician in our practice reviews your history before anything is prescribed.